# GLAUKOS Corp (GKOS)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/glaukos-corp/ JSON: https://steadybase.io/company/glaukos-corp.json Checked Nov 10, 2026. Latest filing read: Oct 28, 2026.

## Company

- Legal name: GLAUKOS Corp
- Ticker: GKOS (NYSE)
- SEC CIK: 0001192448
- Industry: Surgical & Medical Instruments & Apparatus (SIC 3841)
- Headquarters: Aliso Viejo, CA
- Fiscal year ends: December 31
- SEC filer category: Large accelerated filer
- Website: glaukos.com
- LinkedIn: https://www.linkedin.com/company/glaukos-corporation
- Next earnings date: Dec 28, 2026 (estimated from past 8-K timing)

## Key facts

- Revenue: $507.4M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 23, 2026). Source: https://www.sec.gov/Archives/edgar/data/1192448/000119312526061944/0001193125-26-061944-index.html
- Operating income: -$199.6M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 23, 2026). Source: https://www.sec.gov/Archives/edgar/data/1192448/000119312526061944/0001193125-26-061944-index.html
- Net income: -$187.7M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 23, 2026). Source: https://www.sec.gov/Archives/edgar/data/1192448/000119312526061944/0001193125-26-061944-index.html
- SG&A: $331.7M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 23, 2026). Source: https://www.sec.gov/Archives/edgar/data/1192448/000119312526061944/0001193125-26-061944-index.html
- Employees: 1,094 as of Dec 31, 2025, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/1192448/000119312526061944/gkos-20251231.htm
- Shares outstanding: 59,196,870 as of Oct 26, 2026 (10-Q filed Oct 28, 2026). Source: https://www.sec.gov/Archives/edgar/data/1192448/000119312526436400/0001193125-26-436400-index.html
- Auditor: Ernst & Young LLP, Irvine, California, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/1192448/000119312526061944/gkos-20251231.htm

## Business

Glaukos is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal disease. We first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching our first MIGS device, the iStent, commercially in 2012.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/1192448/000119312526061944/gkos-20251231.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income | SG&A |
|---|---|---|---|---|
| Dec 31, 2025 | $507.4M | -$199.6M | -$187.7M | $331.7M |
| Dec 31, 2024 | $383.5M | -$122.4M | -$146.4M | $261.2M |
| Dec 31, 2023 | $314.7M | -$128.7M | -$134.7M | $224.1M |
| Dec 31, 2022 | $282.9M | -$82.3M | -$99.2M | $192.9M |
| Dec 31, 2021 | $294.0M | -$32.9M | -$49.6M | $179.3M |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/glaukos-corp.json

## Officers and directors

- Thomas Burns, Glaukos chairman and chief executive officer. Source: 8-K filed Oct 28, 2026, https://www.sec.gov/Archives/edgar/data/1192448/000119312526436147/gkos-ex99_1.htm
- Thomas William Burns, CHAIRMAN & CEO. Source: Form 4 filed Jun 29, 2026, https://www.sec.gov/Archives/edgar/data/1192448/000164455726000024/0001644557-26-000024-index.htm
- Alex R. Thurman, SVP & CHIEF FINANCIAL OFFICER. LinkedIn: https://linkedin.com/in/athurman. Source: Form 4 filed Aug 11, 2026, https://www.sec.gov/Archives/edgar/data/1192448/000192006126000018/0001920061-26-000018-index.htm
- Alex Thurman, Senior Vice President and Chief Financial Officer. Source: 10-K filed Feb 23, 2026, https://www.sec.gov/Archives/edgar/data/1192448/000119312526061944/gkos-20251231.htm
- Joseph E. Gilliam, PRESIDENT & COO. LinkedIn: https://linkedin.com/in/joseph-gilliam-37325630. Source: Form 4 filed Aug 13, 2026, https://www.sec.gov/Archives/edgar/data/1192448/000170585026000022/0001705850-26-000022-index.htm
- Tomas Navratil, CHIEF DEVELOPMENT OFFICER. LinkedIn: https://linkedin.com/in/tomas-navratil-42a54511. Source: Form 4 filed Sep 28, 2026, https://www.sec.gov/Archives/edgar/data/1192448/000192005326000030/0001920053-26-000030-index.htm
- Aimee S. Weisner, Board member (per proxy). Source: DEF 14A filed Apr 16, 2026, https://www.sec.gov/Archives/edgar/data/1192448/000119312526157829/gkos-20260415.htm
- David F. Hoffmeister, Board member (per proxy). Source: DEF 14A filed Apr 16, 2026, https://www.sec.gov/Archives/edgar/data/1192448/000119312526157829/gkos-20260415.htm
- Denice M. Torres, Board member (per proxy). Source: DEF 14A filed Apr 16, 2026, https://www.sec.gov/Archives/edgar/data/1192448/000119312526157829/gkos-20260415.htm
- Gilbert H. Kliman, MD, Board member (per proxy). Source: DEF 14A filed Apr 16, 2026, https://www.sec.gov/Archives/edgar/data/1192448/000119312526157829/gkos-20260415.htm
- Leana S. Wen, MD, Board member (per proxy). Source: DEF 14A filed Apr 16, 2026, https://www.sec.gov/Archives/edgar/data/1192448/000119312526157829/gkos-20260415.htm
- Marc A. Stapley, Board member (per proxy). Source: DEF 14A filed Apr 16, 2026, https://www.sec.gov/Archives/edgar/data/1192448/000119312526157829/gkos-20260415.htm
- Mark J. Foley, Board member (per proxy). Source: DEF 14A filed Apr 16, 2026, https://www.sec.gov/Archives/edgar/data/1192448/000119312526157829/gkos-20260415.htm
- Thomas W. Burns, Named in proxy. Source: DEF 14A filed Apr 16, 2026, https://www.sec.gov/Archives/edgar/data/1192448/000119312526157829/gkos-20260415.htm

## Recent 8-K events

- Nov 6, 2026: Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1192448/000119312526450710/gkos-20261106.htm
- Oct 28, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1192448/000119312526436147/gkos-20261028.htm
- Aug 3, 2026: Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1192448/000119244826000002/gkos-20260729.htm
- Jul 29, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1192448/000119312526323729/gkos-20260729.htm
- Jun 3, 2026: Item 5.07, Submission of matters to a vote of security holders. Source: https://www.sec.gov/Archives/edgar/data/1192448/000119312526255758/gkos-20260528.htm
- May 4, 2026: Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1192448/000119312526202466/d135093d8k.htm
- Apr 29, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1192448/000119312526191553/gkos-20260429.htm
- Mar 2, 2026: Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1192448/000110465926021885/gkos-20260302x8k.htm
- Feb 17, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1192448/000110465926016410/gkos-20260217x8k.htm
- Jan 13, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1192448/000110465926003321/gkos-20260113x8k.htm

## Insider trades (Form 4)

- Nov 4, 2026: Gilbert H. Kliman (Director) sold 2,500 shares, about $632,500. Source: https://www.sec.gov/Archives/edgar/data/1192448/000119312526450384/0001193125-26-450384-index.htm
- Oct 30, 2026: Tomas Navratil (CHIEF DEVELOPMENT OFFICER) sold 44,436 shares, about $10.6M. Source: https://www.sec.gov/Archives/edgar/data/1192448/000119312526445949/0001193125-26-445949-index.htm
- Oct 5, 2026: Tomas Navratil (CHIEF DEVELOPMENT OFFICER) sold 1,527 shares, about $251,120. Source: https://www.sec.gov/Archives/edgar/data/1192448/000119312526417151/0001193125-26-417151-index.htm
- Sep 25, 2026: Tomas Navratil (CHIEF DEVELOPMENT OFFICER) sold 1,615 shares, about $249,158. Source: https://www.sec.gov/Archives/edgar/data/1192448/000192005326000030/0001920053-26-000030-index.htm
- Sep 16, 2026: Tomas Navratil (CHIEF DEVELOPMENT OFFICER) sold 1,457 shares, about $243,204. Source: https://www.sec.gov/Archives/edgar/data/1192448/000192005326000028/0001920053-26-000028-index.htm
- Aug 28, 2026: Tomas Navratil (CHIEF DEVELOPMENT OFFICER) sold 13,744 shares, about $2.5M. Source: https://www.sec.gov/Archives/edgar/data/1192448/000192005326000026/0001920053-26-000026-index.htm
- Aug 19, 2026: Gilbert H. Kliman (Director) sold 2,500 shares, about $475,000. Source: https://www.sec.gov/Archives/edgar/data/1192448/000129317126000012/0001293171-26-000012-index.htm
- Aug 11, 2026: Joseph E. Gilliam (PRESIDENT & COO) sold 60,000 shares, about $10.8M. Source: https://www.sec.gov/Archives/edgar/data/1192448/000170585026000022/0001705850-26-000022-index.htm
- Aug 7, 2026: Alex R. Thurman (SVP & CHIEF FINANCIAL OFFICER) sold 20,000 shares, about $3.6M. Source: https://www.sec.gov/Archives/edgar/data/1192448/000192006126000018/0001920061-26-000018-index.htm
- Jul 31, 2026: Leana Wen (Director) sold 525 shares, about $88,006. Source: https://www.sec.gov/Archives/edgar/data/1192448/000184759826000010/0001847598-26-000010-index.htm
- Jul 16, 2026: Alex R. Thurman (SVP & CHIEF FINANCIAL OFFICER) sold 10,000 shares, about $1.6M. Source: https://www.sec.gov/Archives/edgar/data/1192448/000192006126000016/0001920061-26-000016-index.htm
- Jul 9, 2026: Alex R. Thurman (SVP & CHIEF FINANCIAL OFFICER) sold 10,000 shares, about $1.6M. Source: https://www.sec.gov/Archives/edgar/data/1192448/000192006126000014/0001920061-26-000014-index.htm
- Jul 6, 2026: Alex R. Thurman (SVP & CHIEF FINANCIAL OFFICER) sold 10,000 shares, about $1.5M. Source: https://www.sec.gov/Archives/edgar/data/1192448/000192006126000012/0001920061-26-000012-index.htm
- Jul 1, 2026: Tomas Navratil (CHIEF DEVELOPMENT OFFICER) sold 716 shares, about $99,567. Source: https://www.sec.gov/Archives/edgar/data/1192448/000192005326000024/0001920053-26-000024-index.htm
- Jun 16, 2026: Tomas Navratil (CHIEF DEVELOPMENT OFFICER) sold 1,537 shares, about $200,855. Source: https://www.sec.gov/Archives/edgar/data/1192448/000192005326000020/0001920053-26-000020-index.htm

## What management said

- "Our record third quarter results reflect successful global execution across our key global commercial and development priorities, leaving us well positioned to sustain our strong growth momentum driven by two transformational growth drivers in iDose TR and Epioxa" Thomas Burns, Glaukos chairman and chief executive officer (8-K filed Oct 28, 2026). Source: https://www.sec.gov/Archives/edgar/data/1192448/000119312526436147/gkos-ex99_1.htm

## Latest filings

- 8-K filed Oct 28, 2026: https://www.sec.gov/Archives/edgar/data/1192448/000119312526436147/gkos-20261028.htm
- 10-K filed Feb 23, 2026: https://www.sec.gov/Archives/edgar/data/1192448/000119312526061944/gkos-20251231.htm
- 10-Q filed Oct 28, 2026: https://www.sec.gov/Archives/edgar/data/1192448/000119312526436400/gkos-20260930.htm
- DEF 14A filed Apr 16, 2026: https://www.sec.gov/Archives/edgar/data/1192448/000119312526157829/gkos-20260415.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/